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For the clinical baseline signature, only the primary tumour volume was selected. The final sig-nature
combined the tumour volume with two independent radiomics features. It achieved moderately
DOI: https://doi.org/10.1016/j.ctro.2020.11.011






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Rabasco Meneghetti, Asier; Zwanenburg, Alex; Leger, Stefan; Leger, Karoline; Troost, Esther G C;
Linge, Annett; Lohaus, Fabian; Schreiber, Andreas; Kalinauskaite, Goda; Tinhofer, Inge; Guberina,
Nika; Guberina, Maja; Balermpas, Panagiotis; von der Grün, Jens; Ganswindt, Ute; Belka, Claus;
Peeken, Jan C; Combs, Stephanie E; Böke, Simon; Zips, Daniel; Krause, Mechthild; Baumann, Michael;
Löck, Steffen (2021). Definition and validation of a radiomics signature for loco-regional tumour control




Definition and validation of a radiomics signature for loco-regional
tumour control in patients with locally advanced head and neck
squamous cell carcinoma
Asier Rabasco Meneghetti a,b, Alex Zwanenburg b,c,d, Stefan Leger b,c,d, Karoline Leger b,c,d,e,
Esther G.C. Troost a,b,c,d,e, Annett Linge b,c,d,e, Fabian Lohaus b,c,d,e, Andreas Schreiber f,
Goda Kalinauskaite g,h, Inge Tinhofer g,h, Nika Guberina i,j, Maja Guberina i,j, Panagiotis Balermpas k,l,
Jens von der Grün k,l, Ute Ganswindtm,n,o,p, Claus Belkam,n,o, Jan C. Peekenm,q,r, Stephanie E. Combsm,q,r,
Simon Böke s,t, Daniel Zips u, Mechthild Krause a,b,c,d,e, Michael Baumann a,b,c,d,e,u, Steffen Löck b,c,e,⇑
a Institute of Radiooncology – OncoRay, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany
bOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden,
Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany
cGerman Cancer Consortium (DKTK), Partner Site, Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
dNational Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital
Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and : Helmholtz Association/Helmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany
eDepartment of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
fDepartment of Radiotherapy, Hospital Dresden-Friedrichstadt, Dresden, Germany
gGerman Cancer Consortium (DKTK) Partner Site Berlin, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
hDepartment of Radiooncology and Radiotherapy, Charité University Medicine Berlin, Germany
iGerman Cancer Consortium (DKTK), Partner Site Essen, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
jDepartment of Radiotherapy, University Hospital Essen, Medical Faculty, University of Duisburg-Essen, Essen, Germany
kGerman Cancer Consortium (DKTK), Partner Site Frankfurt, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
lDepartment of Radiotherapy and Oncology, Goethe-University Frankfurt, Germany
mGerman Cancer Consortium (DKTK), Partner Site Munich Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany
nDepartment of Radiation Oncology, Ludwig-Maximilians-Universität, Munich, Germany
oClinical Cooperation Group, Personalized Radiotherapy in Head and Neck Cancer, Helmholtz Zentrum, Munich, Germany
pDepartment of Radiation Oncology, Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
qDepartment of Radiation Oncology, Technische Universität München, Germany
r Institute of Radiation Medicine (IRM), Helmholtz Zentrum München, Neuherberg, Germany
sGerman Cancer Consortium (DKTK), Partner Site Tübingen, Germany German Cancer Research Center (DKFZ), Heidelberg, Germany
tDepartment of Radiation Oncology, Faculty of Medicine and University Hospital Tübingen, Eberhard Karls Universität Tübingen, Germany
uGerman Cancer Research Center (DKFZ), Heidelberg, Germany
a r t i c l e i n f o
Article history:
Received 18 September 2020
Revised 18 November 2020
Accepted 21 November 2020








a b s t r a c t
Purpose: To develop and validate a CT-based radiomics signature for the prognosis of loco-regional
tumour control (LRC) in patients with locally advanced head and neck squamous cell carcinoma
(HNSCC) treated by primary radiochemotherapy (RCTx) based on retrospective data from 6 partner sites
of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG).
Material and methods: Pre-treatment CT images of 318 patients with locally advanced HNSCC were col-
lected. Four-hundred forty-six features were extracted from each primary tumour volume and then fil-
tered through stability analysis and clustering. First, a baseline signature was developed from
demographic and tumour-associated clinical parameters. This signature was then supplemented by CT
imaging features. A final signature was derived using repeated 3-fold cross-validation on the discovery
cohort. Performance in external validation was assessed by the concordance index (C-Index).
Furthermore, calibration and patient stratification in groups with low and high risk for loco-regional
recurrence were analysed.
Results: For the clinical baseline signature, only the primary tumour volume was selected. The final sig-
nature combined the tumour volume with two independent radiomics features. It achieved moderately
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good discriminatory performance (C-Index [95% confidence interval]: 0.66 [0.55–0.75]) on the validation
cohort along with significant patient stratification (p = 0.005) and good calibration.
Conclusion: We identified and validated a clinical-radiomics signature for LRC of locally advanced HNSCC
using a multi-centric retrospective dataset. Prospective validation will be performed on the primary
cohort of the HNprädBio trial of the DKTK-ROG once follow-up is completed.
 2020 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is the fifth
most incident tumour entity worldwide. Patients suffering from
locally advanced stages show a 5-year survival rate of approxi-
mately 50% [1]. In order to stratify patients for different treatment
options, biomarkers reflecting individual tumour aggressiveness
and response to treatment are required [2]. For HNSCC, several val-
idated biomarkers for the prognosis of treatment outcome have
been developed including tumour volume [3–6], human papilloma
virus (HPV) status [7,8] and gene signatures, e.g. for hypoxia [6,9–
12]. Biomarkers reflecting tumour heterogeneity may help to fur-
ther improve patient stratification.
Radiomics performs a quantitative characterisation of medical
imaging to identify image biomarkers. It employs machine learning
algorithms for the evaluation of disease diagnosis or for the prog-
nosis of treatment outcome and has been applied to several
tumour entities and different imaging modalities [13]. In HNSCC,
radiomics has been applied, e.g. to assess local tumour control
using pre-treatment positron-emission tomography (PET) and
computerised tomography (CT) [14,15] or for HPV status predic-
tion with PET and CT imaging [16,17]. A radiomics signature for
overall survival of HNSCC has been developed using CT imaging,
and was externally validated [18,19]. Radiomics has also been used
to analyse in-treatment CT images for the prognosis of loco-
regional tumour control (LRC) [20], enhancing pre-treatment-
only models.
In our previous work by Leger et al. [21], we aimed to compare
different machine learning algorithms and feature selection meth-
ods in a radiomics analysis for the endpoint LRC in locally
advanced HNSCC based on pre-treatment CT data. We identified
a subset of algorithms that may be applied for radiomics studies
to capture the observed variability in the data. In the present study,
we used these algorithms to develop a specific signature contain-
ing clinical parameters and radiomics features for the prognosis
of LRC in locally advanced HNSCC after primary radiochemother-
apy (RCTx). We applied a modified version of the workflow pre-
sented in [21] consisting of stability analysis, feature clustering,
feature selection, hyperparameter optimisation, model building
and independent validation.
2. Material and methods
2.1. Patient cohort
Radiomics signatures were developed and validated based on
318 patients. All patients were diagnosed with advanced HNSCC,
confirmed by histopathology, and underwent primary RCTx with
curative intent. Dose was prescribed to the tumour region and
adjacent lymph nodes. Treatment doses of up to 76.8 Gy were
delivered in different hyperfractionated, accelerated schedules
(66% of patients) or up to 77 Gy in normofractionated schedules
(34%) with different boost concepts. Concomitant cisplatin (96%)
or mitomycin C (4%) was applied in combination with 5-
Fluorouracil. Patients were allocated to a discovery cohort
(n = 233) and to a validation cohort (n = 85) based on the different
included studies rather than on treatment centre, similar to [21]
(Supplementary Table 1). 147 of the discovery patients were trea-
ted in one of six partner sites of the German Cancer Consortium -
Radiation Oncology Group (DKTK-ROG) between 2005 and 2011
[6]. 86 patients were treated at the University Hospital (UKD, Dres-
den) between 2002 and 2014 [3]. 51 patients in the validation
cohort were treated within a prospective trial (NCT00180180) at
the UKD between 2006 and 2013 [12,22], 20 were treated at the
UKD and the Radiotherapy Centre Dresden-Friedrichstadt between
2005 and 2009, the remaining 14 were treated at the Department
of Radiation Oncology of the University Hospital Tübingen,
between 2008 and 2013 [23].
All analyses were carried out in accordance with the relevant
ethical and legal guidelines and regulations. Ethical approval for
the multicentre retrospective analyses of clinical and imaging data
was obtained from the Ethics Committee of the Technische Univer-
sität Dresden, Germany, EK177042017.
2.2. Study design
Fig. 1 presents the design of our study. The primary endpoint
was LRC, which was calculated from the first day of RCTx to the
day of event or censoring. First, we identified a clinical signature
prognostic for LRC that was based on clinical parameters only,
using the discovery cohort. Then we used radiomics features com-
Fig. 1. Representation of the study design. First, a clinical baseline signature
prognostic for loco-regional tumour control was developed using the discovery
cohort within the machine learning framework. This signature was then supple-
mented by CT radiomics features from the discovery cohort to develop a final
clinical-radiomics signature. Radiomics features were subjected to stability anal-
ysis, volume filtering and clustering before entering the machine learning frame-
work for prognostic modelling. The final signature was externally validated on the
validation cohort.
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puted from the primary gross tumour volume (GTV) delineated in
pre-treatment CT imaging of patients in the discovery cohort to
supplement the clinical signature and create a final clinical-
radiomics signature. A prognostic model was trained in the discov-
ery cohort for both signatures. These models were then assessed on
the validation cohort by calculating the concordance index (C-
Index) as a prognostic measure, by analysing model calibration
and by stratifying patients into groups of low and high risk for
loco-regional recurrence.
2.3. Image pre-processing and feature extraction
Patients received a CT scan for treatment planning prior to
radiotherapy. Image acquisition and reconstruction parameters
are summarised in Supplementary Table 2. The GTV was delin-
eated in each scan by experienced radiation oncologists at our
institution. Voxels in each CT volume were resampled to an isotro-
pic size of 1.0  1.0  1.0 mm3 using cubic splines to compensate
for differing voxel spacing and slice thickness between centres.
Spatial filtering techniques were applied to the base image after
resampling to quantify characteristics such as edges or blobs. A
set of Laplacian of Gaussian (LoG) filters with 5 different kernel
widths (1 mm, 2 mm, 3 mm, 4 mm, 5 mm) were applied individu-
ally to the base image. The five response maps were averaged to a
single image. The entire image pre-processing pipeline was imple-
mented according to the recommendations by the Image Biomar-
ker Standardisation Initiative (IBSI) [24,25].
From the base image and the LoG-transformed image, a set of
18 statistical, 2 local-intensity based, 29 morphological, 37
intensity-histogram-based and 137 texture-based features were
extracted from the GTV leading to 446 features per patient. All fea-
tures were calculated using a 3D approach. Features were com-
puted in full compliance with the IBSI [25]. Radiomics image
processing and feature computation parameters are summarised
in Supplementary Table 3. The entire image processing and extrac-
tion process was done using the publicly available MIRP Python
package [26].
2.4. Stability and clustering of features
Radiomics features should be robust to different sources of vari-
ation, e.g. acquisition parameters and positioning uncertainties, to
allow for external reproduction. As proposed previously, image
augmentation techniques can be used to identify non-robust fea-
tures [27]. For the present study, GTVs were rotated (-4, 2, 0,
2, 4) and volume-changed (-20%, 10%, 10%, 20%) in the discov-
ery cohort, producing 20 new images per patient from which to
analyse individual feature stability. The intra-class correlation
coefficient (ICC) was calculated with 95% confidence interval (CI),
quantifying the similarity of feature values under different pertur-
bations for every feature [28]. For dimensionality reduction and to
only use robust features for model-building, features with the
lower boundary of the 95% CI of the ICC below 0.75 were excluded.
The same features were excluded in the validation cohort.
We subsequently computed the Spearman correlation coeffi-
cient q between robust radiomics features and features in the clin-
ical signature. Every radiomics feature with |q|  0.6 to one of the
features in the clinical signature was removed. Then, we identified
radiomics features that were highly similar by assessing their
mutual correlation. Features were clustered together using hierar-
chical clustering with complete linkage and 1 - |q| as the distance
metric. All features with |q|  0.8 were clustered by cutting the
hierarchical tree at height 0.2. The feature of each cluster with
maximum mutual information with the outcome was chosen as
the representative based on the discovery cohort. The same fea-
tures were selected for the validation cohort.
2.5. Identifying a clinical and clinical-radiomics signature
Two signatures were developed. First, we created a prognostic
clinical signature based on clinical parameters only. Subsequently,
we complemented this signature with radiomics features to create
the final clinical-radiomics signature. Both signatures were devel-
oped using an in-house end-to-end statistical learning software
package. The 4 major processing steps of this package are shown
in Fig. 2: (i) feature pre-processing, (ii) feature selection (detailed
workflow in Supplementary Fig. 1), (iii) hyper-parameter optimisa-
tion for the machine learning algorithms, and (iv) model building
with internal validation.
Overall, steps (i)-(iii) were performed within 33 repetitions of
3-fold cross validation [29] nested in the discovery cohort to iden-
tify an optimal signature, i.e. the steps were repeatedly performed
using the training runs and validated on the validation runs of the
cross-validation runs of the discovery cohort.
(i) Features were transformed using the Yeo-Johnson transfor-
mation to align their distribution to a normal distribution [30].
Afterwards, features were z-transformed to mean zero and stan-
dard deviation one. Both transformations were performed on the
training runs and the resulting transformation parameters were
applied unchanged to the features in the validation fold.
(ii) Based on the results from [21], three supervised feature-
selection algorithms were considered: Spearman correlation
(Spearman), minimal redundancy maximum relevance (MRMR)
[31] and regularised Cox regression (Lasso) [32]. Subsequently,
the features selected by each of these methods were used by three
different prognostic models: Cox regression (Cox), boosted Cox
regression (BGLM-Cox) [33], and random survival forests (RSF)
[34]. All models can work with continuous time-to-event data.
(iii) In order to reduce overfitting in our models, hyperparame-
ters were tuned automatically using the SMBO algorithm based on
bootstrap sampling of the training runs for each model [35].
(iv) A signature was identified as follows. First, features were
ranked according to their occurrence across the 99 cross-
validation runs [36]. Occurrence was defined as the percentage of
runs where a feature was found among the five most important
features. The signature size was defined as the median signature
size across the cross-validation runs. This procedure was con-
ducted for every combination of feature selection method and
model. The resulting nine signatures were then used to train prog-
nostic models on 200 bootstraps of the entire discovery cohort in
order to evaluate their discriminatory power based on the C-
Index. The final signature was chosen based on the highest median
C-Index on the out-of-bag (OOB) data.
The outlined procedure was first performed to identify a clinical
baseline signature. Afterwards, a clinical-radiomics signature was
developed by applying the same modelling procedure to a setup
in which the clinical baseline signature was fixed and supple-
mented by CT imaging features. Both signatures were then used
to train a model based on the entire discovery cohort by repeating
steps (i) and (iii) with their respective machine learning algorithm,
leading to a clinical model and a clinical-radiomics model. These
models were subsequently assessed in the validation cohort.
2.6. Statistical analyses
LRC was compared between discovery and validation cohort via
the log-rank test. Categorical variables of the clinical data were
compared between discovery and validation cohorts by the v2 test,
whereas continuous variables were compared using the Mann-
Whitney-U test. All tests were conducted two-sided, except for
the one-sided permutation test, at p = 0.05 level of significance
on R software version 3.6.0 (R Core Team, 2019).
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Available clinical features were: GTV, age, total dose, gender,
tumour localisation, UICC stage (2010), T stage, N stage, grading,
p16 status, HPV16 DNA status, alcohol and smoking status. Missing
values were imputed by their median value for numerical variables
and by their mode for categorical variables except for alcohol con-
sumption, smoking status and p16 status. These three features
were transformed into two binary features each, representing pos-
itivity and non-availability. The following categorical variables
were binarised: cT stage (0 for cT < 4 and 1 for cT = 4), cN stage
(0 for cN < 2 and 1 cN  2), Grading (0 for Grading  2 and 1 for
Grading > 2) and UICC stage (0 for UICC < 4, 1 for UICC = 4) as in
a previous study [6].
Associations between the final model prognosis and LRC were
evaluated based on the C-Index, for which the median value and
95% confidence interval were reported [37]. Patients were strati-
fied into a low and high risk group using the optimised risk predic-
tion of the discovery cohort [38]. LRC of these groups was
estimated by Kaplan Meier curves, comparisons between groups
were assessed with the log-rank test. Calibration at 24 months
was assessed via the Greenwood Nam d’Agostino test (GND test)
[39]. Correlations between features were assessed by the Spear-
man correlation coefficient (q). Permutation tests were performed
to analyse the importance of the features in the final signatures: for
1000 bootstraps, one selected feature was randomly permuted. The
resulting C-Index distribution on the discovery and validation
cohort was used to define a heuristic p-value as the percentage
of permuted C-Indexes greater than the unpermuted result. This
procedure was repeated for every feature in the final signature.
Differences in discriminatory performance between clinical and
clinical-radiomics models were evaluated using bootstraps. We
created 1000 bootstraps of the validation set, and for each boot-
strap computed the C-Index for both models. We then determined
a p-value by assessing the fraction of bootstraps for which the clin-
ical model had a higher C-Index than the clinical-radiomics model.
3. Results
Clinical characteristics of the discovery and validation cohort
are shown in Table 1. Median follow-up time was 15.8 months
for the discovery cohort and 19.6 months for the validation cohort.
The primary endpoint LRC was not significantly different between
cohorts (p = 0.35, Supplementary Fig. 2). Patients in the validation
cohort presented larger GTV (p = 0.060), younger age (p = 0.015),
and were treated with a marginally higher dose (p < 0.001). Asso-
ciations between clinical variables and LRC are shown in Supple-
mentary Table 4.
First, a clinical baseline signature prognostic for LRC was devel-
oped. All applied feature selection methods selected GTV as the
most important prognostic variable (80% occurrence or more), with
other features rarely chosen (<30% occurrence) (Supplementary
Table 5). The final clinical model was a univariate Cox regression
model containing the GTV. This model showed a median C-Index
of 0.59 with a 95% CI of [0.53–0.65] on the entire discovery cohort
and a C-Index of 0.61 [0.51–0.71] on the validation cohort. Using
an optimised cut-off of 0.982 (29.296 cm3), the risk groups were
significantly different in discovery (p = 0.002) and borderline sig-
nificant in validation (p = 0.052). The model was well calibrated
(discovery: GND = 0.76, slope = 1.09 [0.35–1.83], offset = -0.06
[-0.49–0.38]; validation: GND = 0.80, slope = 1.03 [0.51–1.55],
offset = 0.05 [-0.24–0.34]). Information about model and transfor-
mation parameters can be found in Supplementary Table 6.
Afterwards, the final clinical-radiomics signature based on the
GTV and additional CT radiomics features was developed on the
Fig. 2. Overview of the machine learning framework for signature selection. The major steps of the framework are: (i) pre-processing of the training dataset (the discovery
cohort), (ii) feature selection, (iii) hyperparameter optimization and (iv) model building with internal validation. An ensemble signature was created for every combination of
feature selection and machine learning algorithm by assessing feature occurrence across cross-validation runs in a 33-times repeated 3-fold cross-validation setting
(Frequency selection). Models were created in 200 bootstrap subsamples of the discovery cohort with each corresponding ensemble signature. The concordance index (C-
index) on the out-of-bag data was subsequently computed for each model. The signature and machine learning algorithm with the highest median C-index was selected, out
of nine possible options (Ens. sign. selection). This process was applied first for clinical features. Then we repeated the procedure for CT-based radiomics features,
supplemented by the selected clinical signature, to create a clinical-radiomics signature. Models based on both signatures were then assessed on the basis of discrimination,
stratification and calibration in an external validation cohort.
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discovery cohort. 349 out of 446 stable CT features remained after
performing the stability analysis, i.e. eliminating features with a
lower boundary of the 95% CI of the ICC below 0.75. One hundred
and forty-three of these features that were highly correlated with
GTV (|q|  0.6) were excluded. Clustering of intercorrelated fea-
tures (|q|  0.8) further reduced the number of these features to
61 (see Supplementary Table 7). In combination with the fixed fea-
ture GTV, these CT radiomics features were used in a 3-fold cross
validation setting with 33 repetitions (99 runs) to assess LRC.
Resulting C-Indices of nested training and validation results are
presented in Fig. 3a and 3b, respectively. On average the nested
validation C-Index was 0.59 and there was little variability
between the modelling algorithms. Hyperparameter information
for the different combinations can be found in Supplementary
Table 8.
The best performing signature on 200 bootstraps of the discov-
ery cohort had a signature size 3 and was identified using MRMR
feature selection and the Cox-regression model (C-Index: 0.64
[0.58–0.69], Fig. 3 c,d). The included features were the GTV and
the CT radiomics features log_ngl_hdhge (texture, occurrence:
30.3%) and stat_p10 (statistical, occurrence 20.2%). The two radio-
mics features were weakly correlated among themselves (q = 0.40)
and with the GTV (q  0.51). The feature Log_ngl_hdhge (IBSI:
9QMG) represents big groups of nearby voxels with similarly high
intensity within the GTV and is derived from the lower right quad-
rant of the neighbouring grey level dependence matrix (NGLDM) in
the LoG image. Feature stat_p10 (IBSI: QG58) is related to the
intensity in the entire GTV and describes the 10th percentile inten-
sity of the base image. The features are presented for example
patients in Fig. 4.
The clinical-radiomics signature was finally trained in a Cox
model (C-Index: 0.63 [0.58–0.69]) on the entire discovery cohort
and was successfully validated on the validation cohort (C-Index:
0.66 [0.55–0.75]) for the endpoint LRC. It showed improved dis-
criminatory power compared to the clinical model with a trend
to statistical significance (p = 0.076). Details about model coeffi-
cients and transformation parameters can be found in Table 2.
Based on the validated model, patients were stratified into
groups at high and low risk of loco-regional recurrence using the
optimised risk cutoff value 1.343 of the discovery data. This cutoff
was applied to the validation cohort. Stratified risk groups signifi-
cantly differed in LRC in discovery and validation (p < 0.001 and
p = 0.005, respectively; Fig. 5 a,b). The model was well calibrated
in discovery (GND = 1.00, slope = 1.06 [0.71–1.41], offset = -0.04
[-0.24–0.17]) and validation cohorts (GND = 0.55, slope = 0.93
[0.27–1.59], offset = 0.12 [-0.24–0.47]) (Fig. 5 c,d). The baseline
survival curve can be found in Supplementary Fig. 3. Concerning
feature importance, permutation tests revealed that the all
selected features contributed significantly or showed a statistical
trend for association with LRC in discovery, while the tumour vol-
ume and stat_p10 were significantly associated with LRC in valida-
tion, see Supplementary Table 9.
Table 1
Characteristics of clinical features for discovery (left) and validation (right) cohort along with p-values for homogeneity tests between cohorts.
Discovery cohort Validation cohort
Variable Median (range) Median (range) p-value
GTV (cm3) 29.1 (1.3–321.7), Missing: 0 40.5 (2.7–238.8) Missing: 0 0.061
Age (years) 58.3 (39.2–84.5), Missing: 0 54 (37.0–76.0) Missing: 19 0.015
Total Dose (Gy) 72 (67.8–76.8), Missing: 28 72 (69–77) Missing: 4 <0.001
Number of 233 (%) Number of 85 (%)
Gender 0 (Male) 194 (83.3) 77 (90.6) 0.43
1 (Female) 39 (15.2) 8 (9.4)
Tumour site Oropharynx 101 (43.3) 29 (34.1) 0.38
Hypopharynx 65 (27.9) 28 (32.9)
Larynx 8 (3.4) 5 (5.9)
Oral cavity 59 (25.4) 23 (27.1)
UICC stage (2010) 1 0 (0) 1 (1.2) 0.079
2 1 (0.4) 2 (2.4)
3 17 (7.3) 9 (10.5)
4 212 (90.9) 73 (85.9)
Missing 3 (1.3) 0
cT stage 1 2 (0.8) 2 (2.3) 0.15
2 24 (10.3) 9 (10.6)
3 58 (24.9) 30 (35.3)
4 146 (62.7) 48 (56.4)
Missing 3 (1.3) 0
cN stage 0 38 (16.3) 10 (11.8) 0.23
1 9 (3.9) 8 (9.4)
2 171 (73.4) 64 (75.3)
3 15 (6.4) 3 (3.5)
Grading 0 1 (0.4) 0 0.051
1 6 (2.6) 0
2 135 (57.9) 43 (50.6)
3 62 (26.6) 35 (41.2)
Missing 29 (12.5) 7 (8.2)
p16 status 0 (Negative) 142 (60.9) 57 (67.1) 0.45
1 (Positive) 91 (39.1) 28 (32.9)
HPV16 DNA 0 (Negative) 184 (78.9) 34 (40.0) 1.00
1 (Positive) 22 (9.4) 4 (4.7)
Missing 27 (11,7) 47 (55.3)
Alcohol 0 (No) 69 (29.6) 23 (27.1) 0.72
1 (Regular) 103 (44.2) 25 (29.4)
Missing 61 (26.2) 37 (43.5)
Smoking 0 (Negative) 46 (19.7) 13 (15.3) 0.97
1 (Positive) 185 (79.4) 51 (60.0)
Missing 2 (0.9) 21 (24.7)
GTV: gross tumour volume, UICC: Union international contre le cancer, HPV: human papillomavirus, DNA: deoxyribonucleic acid
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4. Discussion
In the present study, we developed a clinical-radiomics signa-
ture for the prognosis of LRC in patients with locally advanced
HNSCC that received primary RCTx. Using stability analysis and
clustering techniques combined with previously proposed
machine learning algorithms and feature-selection methods, the
final signature contained two features derived from treatment-
planning CT combined with the tumour volume. It was validated
with a C-Index of 0.66. Patient stratification in groups at low and
high risk for loco-regional recurrence showed significant differ-
ences and calibration showed adequate results.
The prognostic performance of the final model in the present
study was similar to the results of the best-performing Cox model
in Leger et al. [21] that also assessed LRC in locally advanced
HNSCC patients based on CT images (C-Index: 0.68). A similar per-
formance was observed by Aerts et al. [18] (C-Index: 0.69) and
Bogowicz et al. [14] (C-Index: 0.72) with their CT-derived signa-
tures that were based on different HNSCC cohorts. While the signa-
ture from Aerts et al. [18] was shown to be highly correlated to
tumour volume [40] and the signature of Bogowicz et al. [14]
included a wavelet-filtered feature, we identified additional radio-
mics features that weakly correlated with tumour volume and did
not include wavelet features, which have been found difficult to
reproduce [41].
All combinations of feature selection and machine learning
algorithms showed the primary tumour volume as the most-
occurring clinical feature. Others, like p16 status or alcohol intake,
were selected much less often. Tumour volume is a validated bio-
marker for overall survival in HNSCC [3–6] and was expected for
radiobiological reasons [42,43], explaining its selection. In our
cohorts, p16 status was not selected since it did not show a signif-
icant association with LRC, even when considering the subgroup of
oropharyngeal tumours. This may in part be explained by the
lower fraction of p16-positive tumours and the higher tumour vol-
ume compared to Linge et al. [3].
Two CT radiomics features were selected in the final signature.
The texture feature log_ngl_hdhge may capture aspects of tumour
microenvironment heterogeneity [44], associated with more recur-
rent tumours in HNSCC [45]. The other feature, stat_p10 represents
the 10th percentile of the intensity histogram within the GTV. It
was shown to weakly correlate with the proliferation index Ki67
Fig. 3. C-Index of models based on different feature-selection methods and machine learning algorithms for the prognosis of loco-regional tumour control. Shown are the
median (95% confidence interval) results from (a) the training runs and (b) the validation runs of 33 times repeated 3-fold cross validation (CV) as well as (c) the results of the
ensemble signatures on 200 bootstrap samples of the discovery cohort evaluated on the out-of-bag data (OOB). In (d), the occurrences of radiomics features in CV are shown
for the best performing signature (red box in (c)). The three features with the highest occurrence were selected for the final radiomics signature (dashed line). The primary
tumour volume (morph_volume) was fixed and thus always occurred. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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in HNSCC [46]. Combining clinical and radiomics features
improved results compared to a clinical-only model for discrimina-
tion and stratification, as was also shown by Zhai et al. [47] for
HNSCC. However, linkage of specific CT radiomics features to
underlying biological mechanisms are not currently well-
established and should be studied in the future.
Model performance may be increased by including additional
imaging modalities: Bogowicz et al. [14] showed that a signature
consisting of CT and PET features had an increased performance
for prognosis of LRC (C-Index: 0.73) compared to PET alone (C-
Index:0.71). Deep learning may be an interesting approach as con-
volutional neural networks (CNN) can learn abstract representa-
tions from images without the need of hand-crafted features.
Using a previously-trained CNN (transfer learning) for LRC progno-
sis in HNSCC an average area under the curve (AUC) of 0.64 was
achieved by Diamant et al. [48], outperforming the 0.5 reached
using that same CNN by Valières et al. [49]. Haarburger et al.[50]
used CNNs to classify patients with non-small cell lung cancer on
a publicly available dataset. Features learned by the CNNs were
then employed for hazard prediction on a Cox model (C-Index:
0.623) , showing a slightly higher performance than the signature
from Aerts et al. (C-Index: 0.609) [18]. However, improved prog-
nostic value compared to the conventional radiomics approach still
must be shown.
Presently, prognostic radiomics models do not yet translate into
clinical application. Firstly, feature reproducibility is an issue as
there is a lack of consensual guidelines on how to extract and
define radiomics features. The IBSI [25] aims to establish such a
consensus and reporting guidelines for the methods employed
for extraction. Secondly, there is underreporting in radiomics stud-
ies as defined by the TRIPOD statement [51], such as handling of
missing data or model specifications like baseline survival, which
Fig. 4. Exemplary CT slices (a,b) and slices of the Logarithm of Gaussian (LoG) filtered images (c,d) of two patients in the discovery cohort (10x10 cm2 crop). Patient 1 showed
highly expressed features in the final signature (tumour volume, stat_p10 and log_ngl_hdhge) and a loco-regional recurrence developed shortly after treatment. For patient 2,
features showed a lower expression and no recurrence was observed during follow-up. For patient 1, a more heterogeneous tumour can be seen, with zones of varying
intensity across the slice, which is emphasised in the LoG image. For patient 2, a more uniform tumour is visible. Red contours mark the primary tumour. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 2
Table with information of features in the final clinical-radiomics model: Hazard Ratio (HR) (95% CI) along with model p-values and transformation parameters for z-transform (z-
shift and z-scale) and Yeo-Johnson parameter (k).
Feature HR [95% CI] p-value z-shift z-scale k
GTV (cm3) 1.248 [0.962–1.619] 0.096 3.457 0.881 0
stat_p10 1.171 [0.983–1.396] 0.077 28.633 62.008 1.5
log_ngl_hdhge 1.215 [0.902–2.095] 0.14 10.968 0.614 0
GTV: gross tumour volume, stat_p10: 10th percentile of intensity histogram, log_ngl_hdhge: high-dependence high-emphasis of the NGL matrix in the Laplacian of Gaussian
image
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leads to limited reproducibility of findings [52]. Furthermore,
prospective studies for validation of radiomics signatures are rare,
which are essential for progression towards clinical application
[53]. To tackle such problems, we have established our radiomics
features in accordance to the IBSI guidelines and report on the
parameters and algorithms used for their extraction, transforma-
tion, stability analysis, and modelling. We use a clear end-to-end
modelling strategy, optimise hyperparameters and resample data
to help reduce overfitting. We also report on the results of our sig-
nature based on three clear aspects on an independent validation
cohort: discrimination, stratification and calibration. Finally, we
aim to apply the signature to prospective data of the HNPrädBio
trial of the DKTK-ROG (www.clinicaltrials.gov, NCT02059668),
which received primary RCTx.
In this study, we developed and validated a clinical-radiomics
signature for assessing LRC in locally advanced HNSCC patients.
This signature combined the primary tumour volume with two
independent CT radiomics features. In the future, we aim to further
validate the signature with data from the prospective HNPrädBio
trial of the DKTK-ROG before potential application in an interven-
tional clinical trial on dose adaptation.
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